FocusOn Healthcare
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Gastroenterology
  • Neurology
  • Oncology
  • Specialties:
  • Women's Health
  • Bone Health
  • Urology
  • Cardiology
  • Head Pain
  • Gastroenterology
  • Neurology
  • Oncology

Test Your Knowledge

Hypercholesterolemia Resource Center Home Page
  1. In the CLEAR Outcomes substudy of patients with a baseline body mass index (BMI) ≥30 kg/m2, to what extent did bempedoic acid 180 mg decrease major adverse cardiovascular events-4 (MACE-4) compared to placebo at follow-up (median 40.7 months)?

    Note: MACE-4 is a composite of myocardial infarction, stroke, coronary revascularization, and cardiovascular death.
  2. Which of the following is a mechanism of action of bempedoic acid that leads to a reduction in low-density lipoprotein cholesterol (LDL-C)?
  3. The benefit of bempedoic acid on reducing major adverse cardiovascular events in the CLEAR Outcomes trial subanalysis in patients with obesity (BMI ≥30 kg/m2) is believed to be related to the reduction in _________. (Select all that apply)
  4. In a prespecified analysis of cardiovascular outcomes by sex in the CLEAR Outcomes trial, bempedoic acid reduced the primary endpoint of major adverse cardiovascular events-4 (MACE-4) compared to placebo ______.

    Note: MACE-4 is a composite of myocardial infarction, stroke, coronary revascularization, and cardiovascular death.
  5. In the CLEAR Outcomes trial population, which was composed of patients with high low-density lipoprotein cholesterol (LDL-C) levels who were intolerant to statin treatment, which baseline factor better predicted the risk of major adverse cardiovascular events-4 (MACE-4)?

    Note: MACE-4 is a composite of myocardial infarction, stroke, coronary revascularization, and cardiovascular death.

References

  1. Bays HE, et al. Bempedoic acid for the prevention of cardiovascular events in people with obesity: a CLEAR outcomes subset analysis. J Am Heart Assoc. 2025;14:e037898. doi: 10.1161/JAHA.124.037898
  2. Linnenberger R, et al. Statins and bempedoic acid: different actions of cholesterol inhibitors on macrophage activation. Int J Mol Sci. 2021;22(22):12480. doi: 10.3390/ijms222212480.
  3. Feingold KR. Cholesterol Lowering Drugs. In: Feingold KR, Ahmed SF, Anawalt B et al, eds. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000. https://www.ncbi.nlm.nih.gov/books/NBK395573/. Updated February 12, 2024.
  4. Cho L, et al. Impact of bempedoic acid on cardiovascular outcomes by sex. Circulation. 2024;149:1775–1777. doi: 10.1161/CIRCULATIONAHA.123.067691
  5. Ridker PM, et al. Inflammation and cholesterol as predictors of cardiovascular events among 13970 contemporary high-risk patients with statin intolerance. Circulation. 2024;149:28–35. doi: 10.1161/CIRCULATIONAHA.123.066213
FocusOn logo
  • About FocusOn
  • Privacy Policy
  • Terms of Use

© 2025 Wolters Kluwer. All right reserved.

Your Privacy

To give you the best possible experience we use cookies and similar technologies. We use data collected through these technologies for various purposes, including to enhance website functionality, remember your preferences, show the most relevant content, and show the most useful ads. You can select your preferences by clicking the link. For more information, please review our Privacy and Cookie Policy.

|
|

Cookie Policy

Information about our use of cookies

Wolters Kluwer ("we" or "us") wants to inform you about the ways we process your personal information. In this Privacy & Cookie Notice we explain what personal information we collect, use and disclose.

Personal information means any data relating to an individual who can be identified, directly or indirectly, based on that information. This may include information such as names, contact details, (online) identification data, online identifiers, or other characteristics specific to that individual.

Read More